Recurrence and risk factors in cured patients with vitiligo: A real-life single-center retrospective study

被引:0
|
作者
Xu, Wei [1 ,2 ,3 ]
Qiu, Zhijin [1 ,2 ,3 ]
Li, Chaolan [1 ,2 ,3 ]
Wang, Yuyi [1 ,2 ,3 ]
Lin, Mao [1 ,2 ,3 ]
Liu, Yi [1 ,2 ,3 ]
Wen, Yating [1 ,2 ,3 ,4 ]
Zheng, Wenhao [1 ,2 ,3 ,4 ]
机构
[1] Chongqing Hosp Tradit Chinese Med, Dept Dermatol, Chongqing, Peoples R China
[2] Chongqing Hosp Tradit Chinese Med, Chongqing Clin Res Ctr Dermatol, Chongqing, Peoples R China
[3] Chongqing Hosp Tradit Chinese Med, Chongqing Key Lab Integrat Dermatol Res, Chongqing, Peoples R China
[4] Chongqing Hosp Tradit Chinese Med, Dept Dermatol, 40 Daomenkou St, Chongqing 400011, Peoples R China
关键词
recurrence; risk factors; vitiligo; 0.1-PERCENT; EFFICACY;
D O I
10.1111/jocd.15637
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
BackgroundThe risk of recurrence after successful repigmentation in vitiligo has attracted attention from both patients and clinicians. ObjectivesThe recurrence rate and risk factors in cured patients with vitiligo were analyzed to improve clinical prevention and treatment. MethodsClinical records of 76 patients with vitiligo who demonstrated at least 80% repigmentation were analyzed retrospectively. Single-factor analysis of variance and binary logistic regression analysis was employed to screen the risk factors of vitiligo recurrence. ResultsAmong the 76 cured patients, 26 relapsed (total recurrence rate of 34.2%). Among these, 20 relapsed within one year (recurrence rate of 26.3%). Single-factor analysis of variance revealed significant differences (p < 0.05) with the age of onset (yr), distribution of onset, and oral traditional Chinese medicine (TCM) intake between the recurrence and nonrecurrence groups. Binary logistic regression analysis displayed that the age of onset (yr) (p = 0.015, OR = 1.051), distribution of onset (p = 0.046, OR = 0.194), and oral TCM (p = 0.018, OR = 4.360) are significant risk factors for vitiligo recurrence. ConclusionA total relapse rate of 34.2% was observed in cured vitiligo patients. The age of onset (yr), distribution of onset, and oral TCM are risk factors for vitiligo recurrence. The necessary interventions should be considered on these factors for reducing the recurrence rate of vitiligo.
引用
收藏
页码:1680 / 1684
页数:5
相关论文
共 50 条
  • [31] Dupilumab Therapy of Prurigo Nodularis: A Single-Center, Real-Life Observational Study
    Jing, Wenwen
    Yang, Danyang
    Liu, Xin
    Li, Li
    Lu, Tao
    Li, Xiaoli
    DERMATOLOGIC THERAPY, 2023, 2023
  • [32] Risk Factors for Cardiac Complications in Patients With Pheochromocytoma and Paraganglioma: A Retrospective Single-Center Study
    Zhao, Lin
    Meng, Xu
    Mei, QiMin
    Fan, Hua
    Liu, YeCheng
    Zhou, XianLiang
    Zhu, HuaDong
    Zhang, ShuYang
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [33] The real-life efficacy of methotrexate in vitiligo: A retrospective study and literature review
    Speeckaert, Reinhart
    van Geel, Nanja
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (11) : 2267 - 2269
  • [34] Perampanel as an Add-On Therapy in Patients with Refractory Status Epilepticus and Postanoxic Encephalopathy: A Real-Life Single-Center Retrospective Cohort Study
    Cutillo, Gianni
    Bonacchi, Raffaello
    Vabanesi, Marco
    Cecchetti, Giordano
    Bellini, Anna
    Filippi, Massimo
    Fanelli, Giovanna F.
    NEUROCRITICAL CARE, 2024, 41 (03) : 942 - 949
  • [35] Switching from immediate- to extended-release cysteamine in nephropathic cystinosis patients: a retrospective real-life single-center study
    Ahlenstiel-Grunow, Thurid
    Kanzelmeyer, Nele K.
    Froede, Kerstin
    Kreuzer, Martin
    Drube, Jens
    Lerch, Christian
    Pape, Lars
    PEDIATRIC NEPHROLOGY, 2017, 32 (01) : 91 - 97
  • [36] Switching from immediate- to extended-release cysteamine in nephropathic cystinosis patients: a retrospective real-life single-center study
    Thurid Ahlenstiel-Grunow
    Nele K. Kanzelmeyer
    Kerstin Froede
    Martin Kreuzer
    Jens Drube
    Christian Lerch
    Lars Pape
    Pediatric Nephrology, 2017, 32 : 91 - 97
  • [37] PHARMACOKINETIC STUDY IN 15 PATIENTS WITH HAEMOPHILIA A CANDIDATE TO SWITCH TO RFVIIIFC: REAL-LIFE SINGLE-CENTER EXPERIENCE
    Ceglie, T.
    Ricca, I.
    Pagliarino, M.
    Pollio, B.
    HAEMOPHILIA, 2020, 26 : 59 - 60
  • [38] Apremilast for the treatment of palmo-plantar non-pustular psoriasis: A real-life single-center retrospective study
    Pavia, Giulia
    Gargiulo, Luigi
    Cortese, Andrea
    Valenti, Mario
    Sanna, Federica
    Borroni, Riccardo G.
    Costanzo, Antonio
    Narcisi, Alessandra
    DERMATOLOGIC THERAPY, 2022, 35 (02)
  • [39] Risk Factors of Infection in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone (Rd) Regimen: Real-Life Results of a Large Single-Center Study
    Mikulski, Damian
    Robak, Pawel
    Ryzewska, Wiktoria
    Stanczak, Kamila
    Koscielny, Kacper
    Gora-Tybor, Joanna
    Robak, Tadeusz
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (19)